Search Results

You are looking at 1-10 of 73

Anesthetic Efficacy of Bupivacaine Solutions in Inferior Alveolar Nerve Block

Maria Cristina Volpato DDS, PhD,

José Ranali DDS, PhD,

Juliana Cama Ramacciato DDS, PhD,

Patrícia Cristine de Oliveira DDS, MS,

Glaúcia Maria Bovi Ambrosano PhD, and

Francisco Carlos Groppo DDS, PhD

Article Category: Other

Volume/Issue: Volume 52: Issue 4

Online Publication Date: Jan 01, 2005

DOI: 10.2344/0003-3006(2005)52[132:AEB]2.0.CO;2

Page Range: 132 – 135

Racemic bupivacaine has been used as a local anesthetic in medicine and dentistry for many years. The 2 main indications for its use in dentistry are lengthy procedures and management of postoperative pain, as in endodontic, surgical, and periodontal procedures, among others. 1 Although no case of toxicity has been documented in dentistry, a number of authors have reported its potent cardiac toxic effects, even in small doses. 2 Studies that compared racemic bupivacaine and levobupivacaine have shown less toxicity for the latter. 3 , 4 Since 2000, a

Download PDF

Liposomal Bupivacaine Use in Third Molar Impaction Surgery: INNOVATE Study

Stuart E. Lieblich DMD and

Hassan Danesi MD

Article Category: Research Article

Volume/Issue: Volume 64: Issue 3

Online Publication Date: Jan 01, 2017

DOI: 10.2344/anpr-64-02-03

Page Range: 127 – 135

analgesia is considered one of the most important advancements in dental science during the past century. 21 Infiltration with local anesthetics at the surgical site represents an effective approach to postsurgical analgesia that can be used as part of a multimodal approach to pain management. Local administration minimizes the risk of systemic adverse events (AEs); however, the efficacy of local anesthetics is limited by their short duration of action (typically ≤8–10 hours). 22 Liposomal bupivacaine (EXPAREL, bupivacaine liposome injectable suspension; Pacira

Download PDF

Figure 2 ; Study population: disposition of subjects. LB indicates liposomal bupivacaine; NRS, numeric rating scale; and ITT, intent-to-treat.

Stuart E. Lieblich and

Hassan Danesi

Figure 2

Study population: disposition of subjects. LB indicates liposomal bupivacaine; NRS, numeric rating scale; and ITT, intent-to-treat.

Figure 3. ; Diagram of liposomal bupivacaine particle in DepoFoam vehicle. Image supplied courtesy of Pacira Pharmaceuticals Inc.

Mana Saraghi and

Elliot V. Hersh

Figure 3.

Diagram of liposomal bupivacaine particle in DepoFoam vehicle. Image supplied courtesy of Pacira Pharmaceuticals Inc.

; Long-acting local anesthetic agent preference. Most respondents who use a long-acting local anesthetic agent preferred bupivacaine (Marcaine). Q, survey item number.

Steven Halepas,

Cameron Christiansen,

Alia Koch,

Shahid R. Aziz,

David M. Shafer, and

Elie M. Ferneini

; Incidence of first mandibular premolar anesthesia (pulpal anesthesia) as determined by lack of response to electrical pulp testing (percentage of 80 readings without response) versus time for the 2 local anesthetic solutions tested.

Maria Cristina Volpato,

José Ranali,

Juliana Cama Ramacciato,

Patrícia Cristine de Oliveira,

Glaúcia Maria Bovi Ambrosano, and

Francisco Carlos Groppo

Figure 1 ; Infiltration technique. Arrows denote illustrative infiltration sites. Images courtesy of Stuart E. Lieblich, DMD.

Stuart E. Lieblich and

Hassan Danesi

Figure 1

Infiltration technique. Arrows denote illustrative infiltration sites. Images courtesy of Stuart E. Lieblich, DMD.

Figure 3 ; A. Cumulative AUC of NRS pain intensity scores at 24, 48, 72, and 96 hours postsurgery (primary efficacy [ITT] population). AUC indicates area under the curve; NRS, numeric rating scale; and ITT, intent-to-treat. B. Cumulative AUC of NRS pain intensity scores at 24, 48, 72, and 96 hours postsurgery (per-protocol population). *P < .05 versus placebo.

Stuart E. Lieblich and

Hassan Danesi

Figure 3

A. Cumulative AUC of NRS pain intensity scores at 24, 48, 72, and 96 hours postsurgery (primary efficacy [ITT] population). AUC indicates area under the curve; NRS, numeric rating scale; and ITT, intent-to-treat. B. Cumulative AUC of NRS pain intensity scores at 24, 48, 72, and 96 hours postsurgery (per-protocol population). *P < .05 versus placebo.

Figure 4 ; A. Mean scores for subjects' satisfaction with postsurgical pain control assessed using a 5-point Likert scale where 1 = extremely dissatisfied and 5 = extremely satisfied (primary efficacy [intent-to-treat] population). B. Mean scores for subjects' satisfaction with postsurgical pain control assessed using a 5-point Likert scale where 1 = extremely dissatisfied and 5 = extremely satisfied (per-protocol population).

Stuart E. Lieblich and

Hassan Danesi

Figure 4

A. Mean scores for subjects' satisfaction with postsurgical pain control assessed using a 5-point Likert scale where 1 = extremely dissatisfied and 5 = extremely satisfied (primary efficacy [intent-to-treat] population). B. Mean scores for subjects' satisfaction with postsurgical pain control assessed using a 5-point Likert scale where 1 = extremely dissatisfied and 5 = extremely satisfied (per-protocol population).

Three Newly Approved Analgesics: An Update

Mana Saraghi DMD and

Elliot V. Hersh DMD, MS, PhD

Article Category: Other

Volume/Issue: Volume 60: Issue 4

Online Publication Date: Jan 01, 2013

DOI: 10.2344/0003-3006-60.4.178

Page Range: 178 – 187

effects from each drug class. This article presents and reviews 3 new analgesic agents that may be useful in treating postoperative dental and maxillofacial pain: tapentadol immediate release (Nucynta) diclofenac potassium soft gelatin capsules (Zipsor) and bupivacaine liposome injectable suspension (EXPAREL). TAPENTADOL IMMEDIATE-RELEASE Tapentadol immediate-release was granted approval by the US Food and Drug Administration (FDA) in November 2008 and is indicated for the treatment of moderate to severe pain. 7 , 8 Tapentadol is a both a mu

Download PDF

About Issues Author Information Subscriptions

Permissions Advertising Privacy Policy Facebook

Twitter FAQ Help

eISSN: 1878-7177

ISSN: 0003-3006